RxDoctor Payments Data

Dana Conner, MD

Undersea and Hyperbaric Medicine · Blairsville, GANPI 1356344048

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Melinta Therapeutics, LLC at 53.0% of the total. Reporting peaked in 2021 at $784 and has fallen 53.4% since, to $365 in 2025.

$3,651in general payments, 2019–2025

Across 250 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Melinta Therapeutics, LLC$2K
  • Paratek Pharmaceuticals, Inc.$566
  • Smith+Nephew$280
  • Polymedics Innovations Inc.$133
  • Hydrofera LLC$84
  • Organogenesis Inc.$81
  • plus $573 from 19 others

What the payments were for

  • Food & beverage$3,54997%
  • Education$1033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few undersea and hyperbaric medicine providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$156,778
Medicare patients
265
Services billed
2,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate38$246,060
Tobramycin Sulfate38$74,692
Linezolid35$3,815
Meropenem12$3,280
Daptomycin13$2,716
Vancomycin Hcl15$2,476
CeftriaxoneCeftriaxone Sodium11$1,425
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam11$995
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav60$490
Doxycycline Hyclate45$425
Levofloxacin74$366
Mupirocin12$141
Ciprofloxacin Hcl17$128
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim22$98
Prednisone20$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$566$246,06038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few undersea and hyperbaric medicine providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other undersea and hyperbaric medicine in Blairsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →